Evidence map›Paper›PMID 35626021›Full record

ArticleCancers2022

Identification of Carcinogenesis and Tumor Progression Processes in Pancreatic Ductal Adenocarcinoma Using High-Throughput Proteomics.

Lucía Trilla-Fuertes, Angelo Gámez-Pozo, María Isabel Lumbreras-Herrera, Rocío López-Vacas, Victoria Heredia-Soto, Ismael Ghanem, Elena López-Camacho, Andrea Zapater-Moros, María Miguel, Eva M Peña-Burgos and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Proteomics in pancreatic cancer.Biomarker research · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Functional and Clinical Proteomic Exploration of Pancreatic Cancer.Molecular & cellular proteomics : MCP · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Lucía Trilla-FuertesMolecular Oncology & Pathology Laboratory, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.ORCID 0000-0002-4452-3474
Angelo Gámez-PozoMolecular Oncology & Pathology Laboratory, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.
María Isabel Lumbreras-HerreraMolecular Oncology & Pathology Laboratory, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.
Rocío López-VacasMolecular Oncology & Pathology Laboratory, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.
Victoria Heredia-SotoMolecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.
Ismael GhanemMedical Oncology Service, Hospital Universitario La Paz, 28046 Madrid, Spain.ORCID 0000-0002-1859-0737
Elena López-CamachoBiomedica Molecular Medicine SL, 28049 Madrid, Spain.
Andrea Zapater-MorosBiomedica Molecular Medicine SL, 28049 Madrid, Spain.
María MiguelMolecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.
Eva M Peña-BurgosPathology Department, Hospital Universitario La Paz, 28046 Madrid, Spain.
Elena PalaciosPathology Department, Hospital Universitario La Paz, 28046 Madrid, Spain.
Marta De UribePathology Department, Hospital Universitario La Paz, 28046 Madrid, Spain.
Laura GuerraPathology Department, Hospital Universitario La Paz, 28046 Madrid, Spain.
Antje DittmannFunctional Genomics Center Zurich, University of Zurich/ETH Zurich, 8057 Zurich, Switzerland.
Marta MendiolaMolecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.
Juan Ángel Fresno VaraMolecular Oncology & Pathology Laboratory, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.ORCID 0000-0003-1527-1252
Jaime FeliuBiomedical Research Networking Center on Oncology-CIBERONC, ISCIII, 28029 Madrid, Spain.ORCID 0000-0003-4867-1420
Hospital Universitario La Paz · ESUniversity of Zurich · CH

Funding

EPIC-XS Consortium 823839Instituto de Salud Carlos III PI18/01604
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with an overall 5-year survival rate of just 5%. A better understanding of the carcinogenesis processes and the mechanisms of the progression of PDAC is mandatory. Fifty-two PDAC patients treated with surgery and adjuvant therapy, with available primary tumors, normal tissue, preneoplastic lesions (PanIN), and/or lymph node metastases, were selected for the study. Proteins were extracted from small punches and analyzed by LC-MS/MS using data-independent acquisition. Proteomics data were analyzed using probabilistic graphical models, allowing functional characterization. Comparisons between groups were made using linear mixed models. Three proteomic tumor subtypes were defined. T1 (32% of patients) was related to adhesion, T2 (34%) had metabolic features, and T3 (34%) presented high splicing and nucleoplasm activity. These proteomics subtypes were validated in the PDAC TCGA cohort. Relevant biological processes related to carcinogenesis and tumor progression were studied in each subtype. Carcinogenesis in the T1 subtype seems to be related to an increase of adhesion and complement activation node activity, whereas tumor progression seems to be related to nucleoplasm and translation nodes. Regarding the T2 subtype, it seems that metabolism and, especially, mitochondria act as the motor of cancer development. T3 analyses point out that nucleoplasm, mitochondria and metabolism, and extracellular matrix nodes could be involved in T3 tumor carcinogenesis. The identified processes were different among proteomics subtypes, suggesting that the molecular motor of the disease is different in each subtype. These differences can have implications for the development of future tailored therapeutic approaches for each PDAC proteomics subtype.

Indexed as

carcinogenesishigh-throughput proteomicsmolecular profilespancreatic ductal adenocarcinomatumor progression

Identifiers

PMID35626021
PMCPMC9139847
OpenAlexW4280651559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.